The big picture: DDi (Drug Development informatics) has been honored as the 'Best Global Regulatory & Clinical Development Partner 2025' by Global Health & Pharma (GHP) for its innovative solutions in the life sciences industry. This award highlights DDi's commitment to streamlining regulatory workflows and accelerating clinical development worldwide. Why it matters: This recognition underscores the increasing demand for specialized technology and expertise in navigating complex global regulatory landscapes, impacting talent needs and operational efficiency for life sciences organizations. Between the lines: - DDi provides regulatory and clinical solutions, including intelligence, trial management, and data integration. - The award acknowledges DDi's focus on innovation, compliance, and customer-centric approaches. - DDi is a privately owned company with global offices in the USA, UK, India, and Singapore. Staffing & HR impact: The demand for specialized talent in regulatory affairs and clinical development informatics will likely increase, driving competition for skilled professionals and potentially impacting recruiter mobility and compensation in the life sciences sector. Companies like DDi will need robust talent acquisition strategies to support their expanding global footprint and technological capabilities. The bottom line: DDi's award signals a growing emphasis on technological solutions and expert partnerships to manage the intricate regulatory and clinical development processes in the global health sector.